Details for New Drug Application (NDA): 070755
✉ Email this page to a colleague
NDA 070755 describes LITHIUM CITRATE, which is a drug marketed by Hikma, Pai Holdings Pharm, Rubicon, and Sciegen Pharms Inc, and is included in four NDAs. It is available from three suppliers. Additional details are available on the LITHIUM CITRATE profile page.
The generic ingredient in LITHIUM CITRATE is lithium citrate. There are fifteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lithium citrate profile page.
The generic ingredient in LITHIUM CITRATE is lithium citrate. There are fifteen drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lithium citrate profile page.
Summary for 070755
| Tradename: | LITHIUM CITRATE |
| Applicant: | Pai Holdings Pharm |
| Ingredient: | lithium citrate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | EQ 300MG CARBONATE/5ML | ||||
| Approval Date: | May 21, 1986 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
